ESOC 2026 | rFVIIa in patients with ICH taking aspirin: analysis of FASTEST
Joseph Broderick, MD, University of Cincinnati, Cincinnati, OH, discusses an analysis of the FASTEST study (NCT03496883) exploring the impact of recombinant factor VIIa (rFVIIa) in patients with intracerebral hemorrhage (ICH) taking aspirin. Prof. Broderick highlights that patients taking aspirin were more likely to experience larger hemorrhage growth, but rFVIIa significantly reduced this growth. This interview took place at the 12th European Stroke Organisation Conference (ESOC) in Maastricht, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so what we were looking at in our FASTEST study is also the patients who have or were taking an antiplatelet medicine prior to their hemorrhage. And what we know is this is a risk factor from other studies of more likelihood that the ICH will expand and grow. And indeed, that’s what we found. So we found that these groups, this group who had an antiplatelet medicine, most all of them were aspirin, were much more likely to have larger growth of hemorrhage compared to those that weren’t on an antiplatelet agent...
Yeah, so what we were looking at in our FASTEST study is also the patients who have or were taking an antiplatelet medicine prior to their hemorrhage. And what we know is this is a risk factor from other studies of more likelihood that the ICH will expand and grow. And indeed, that’s what we found. So we found that these groups, this group who had an antiplatelet medicine, most all of them were aspirin, were much more likely to have larger growth of hemorrhage compared to those that weren’t on an antiplatelet agent. And that factor VIIa almost completely eliminated that growth in that group. So like going from bleeding in the brain and in the blood and the ventricles from around 18cc, 18 milliliters to about 1.75 milliliters in those who got factor VIIa. So a big decrease. So what that shows is that factor VIIa can reverse bleeding in patients who are on an antiplatelet agent.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
